Yourgene Health PLC (YGEN.L) DHSC contract award for COVID Winter surge testing

Third contract awarded under PHE National Microbiology Framework Agreement

Manchester, UK – 23 December 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that Yourgene Genomic Services (‘YGS’) has been awarded a contract for the provision of laboratory capacity to support the Winter Surge COVID-19 testing by the Department of Health & Social Care (DHSC), running until 31 March 2022.

The ” Mini Tender Winter Surge Capacity (C47365)” contract is the third DHSC contract awarded to the Group this year under the Public Health England National Microbiology Framework Agreement. The previous two awards include the COVID-19 PCR surge testing announced on 19 August 2021 and the recent UKHSA sequencing contract announced on 14 December 2021.

Lyn Rees, Chief Executive Officer, commented: ” This is another strong endorsement of our progress and we are pleased to be able to support the nation’s COVID testing effort. Actual value for this contract will depend on the services purchased, with no committed spend at this moment in time, but we look forward to updating shareholders on the progress over time.”

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this announcement.

Yourgene Health plc

Lyn Rees, Chief Executive Officer

Tel: +44 (0)161 669 8122

investors@yourgene-health.com

Barry Hextall, Chief Financial Officer

Joanne Cross, Director of Marketing

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group’s flagship products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics , Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene’s geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Subscribe To Our Daily Update

Share via
Copy link
Malcare WordPress Security